Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR
Copyright policy )Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR
AbstractThe main targets for neutralizing anti-hepatitis C virus (HCV) antibodies (HCV-nAbs) are the E1 and E2 envelope glycoproteins. We have studied the characteristics of HCV-nAbs through a retrospective study involving 29 HIV/HCV-coinfected patients who achieved sustained virological response (SVR) with peg-IFNα + ribavirin anti-HCV therapy. Plasma samples at baseline and week 24 after SVR were used to perform neutralization assays against five JFH1-based HCV recombinant viruses coding for E1 and E2 from genotypes 1a (H77), 1b (J4), 2a (JFH1), 3a (S52) and 4a (ED43). At baseline, the majority of plasma samples neutralized 1a, 1b, 2a, and 4a, but not 3a, genotypes. Twenty-four weeks following SVR, most neutralizing titers declined substantially. Furthermore, titers against 3a and 2a were not detected in many patients. Plasma samples with high HCV-nAb titers neutralized all genotypes, and the highest titers at the starting point correlated with the highest titers at week 24 after SVR. In conclusion, high titers of broad-spectrum HCV-nAbs were detected in HIV/HCV-coinfected individuals, however, those titers declined soon after SVR.
Adult, Male, SVR, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Serum Globulins::Immunoglobulins::Antibodies::Antibodies, Viral::Hepatitis Antibodies::Amino Acids, Peptides, and Proteins::Proteins::Hepatitis C Antibodies, Genotype, Sustained Virologic Response, Medicina, Science, HIV Infections, Hepacivirus, Antiviral Agents, Antibodies, Article, HIV/HCV-coinfected patients, Cell Line, Tumor, Ribavirin, Humans, Medicaments antivírics, Phylogeny, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::aminoácidos, péptidos y proteínas::proteínas::aminoácidos, péptidos y proteínas::proteínas::globulinas::globulinas séricas::inmunoglobulinas::anticuerpos::anticuerpos víricos::anticuerpos de las hepatitis::antciuerpos de la hepatitis C, Retrospective Studies, Hepatitis C virus, Q, DISEASES::Immune System Diseases::Immunologic Deficiency Syndromes::HIV Infections::HIV Seropositivity, R, Interferon-alpha, ENFERMEDADES::enfermedades del sistema inmune::síndromes de inmunodeficiencia::infecciones por VIH::seropositividad al VIH, Hepatitis C Antibodies, Middle Aged, Viral Load, anti-HCV antibodies, Antibodies, Neutralizing, Hepatitis C, CHEMICALS AND DRUGS::Nucleic Acids, Nucleotides, and Nucleosides::Nucleosides::Ribonucleosides::Ribavirin, Antirheumatic Agents, Medicine, Infeccions per VIH, Female, COMPUESTOS QUÍMICOS Y DROGAS::nucleótidos y nucleósidos de ácidos nucleicos::nucleósidos::ribonucleósidos::ribavirina
Adult, Male, SVR, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Serum Globulins::Immunoglobulins::Antibodies::Antibodies, Viral::Hepatitis Antibodies::Amino Acids, Peptides, and Proteins::Proteins::Hepatitis C Antibodies, Genotype, Sustained Virologic Response, Medicina, Science, HIV Infections, Hepacivirus, Antiviral Agents, Antibodies, Article, HIV/HCV-coinfected patients, Cell Line, Tumor, Ribavirin, Humans, Medicaments antivírics, Phylogeny, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::aminoácidos, péptidos y proteínas::proteínas::aminoácidos, péptidos y proteínas::proteínas::globulinas::globulinas séricas::inmunoglobulinas::anticuerpos::anticuerpos víricos::anticuerpos de las hepatitis::antciuerpos de la hepatitis C, Retrospective Studies, Hepatitis C virus, Q, DISEASES::Immune System Diseases::Immunologic Deficiency Syndromes::HIV Infections::HIV Seropositivity, R, Interferon-alpha, ENFERMEDADES::enfermedades del sistema inmune::síndromes de inmunodeficiencia::infecciones por VIH::seropositividad al VIH, Hepatitis C Antibodies, Middle Aged, Viral Load, anti-HCV antibodies, Antibodies, Neutralizing, Hepatitis C, CHEMICALS AND DRUGS::Nucleic Acids, Nucleotides, and Nucleosides::Nucleosides::Ribonucleosides::Ribavirin, Antirheumatic Agents, Medicine, Infeccions per VIH, Female, COMPUESTOS QUÍMICOS Y DROGAS::nucleótidos y nucleósidos de ácidos nucleicos::nucleósidos::ribonucleósidos::ribavirina
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).2 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!